Our Guarantee

Payment Methods

Shipping Policy

Returns Policy
View cart


Acticoat

Actiformcool
Actisorb
Activon
Alcowipes
Algisite
Algivon
Alldress
Allevyn
Aquacel
Aquaform
Atrauman
Avance
Azowipe
Bactigras
Biatain
Bioclusive
Blue Catering
Carboflex
Carbopad
Cavi-Care
Cica-Care
Clinisorb
Combiderm
Comfeel
Cutinova
C-View
Dispos-A-Glov
Dressit
Duoderm
Foam Dressing Granuflex
Granugel
Hydrocoll
Hydrosorb
Inadine
Instillagel
Intrasite
Iodoflex
Iodosorb
IV3000
Jelonet
K4
Kaltostat Lite
Lyofoam
Mepiform
Mepilex
Mepitel
Mepore
Mesitran
Mesorb
NA dressings
N-A Ultra
Nurse It
Nu Gel
Opsite
Polymem
Primapore
Prisma
Promogran
Replicare
Silvercel
Softpore
Sorbsan
Stomahesive
Tegaderm
Tegasorb
Tielle
Topper
Transorbent
Tricotex
Urgocell
Urgosorb
Urgotul
Versiva



Dressings > Urgotul
Urgotul Dressings




PK/10 Our Price = $ 105.16
PK/10 Our Price = $ 85.68
PK/10 Our Price = $ 348.84
PK/25 Our Price = $ 262.87
PK/10 Our Price = $ 265.68
PK/16 Our Price = $ 475.78


Key Features of Urgotul Dressings

Urgotul belongs to a new class of non-adherent dressings: the lipidocolloid dressings. It is composed of an open weave polyester mesh impregnated with hydrocolloid polymers dispersed within petrolatum. The first clinical trial data are presented. Efficacy and safety were evaluated in a multicentre non-comparative trial involving 92 patients treated to healing or up to 4 weeks. Adult outpatients with acute wounds (n = 34), leg ulcers (n = 24), other chronic wounds (n = 14) or with second-degree burns (n = 20) were included. Results showed 32.4% (n = 11) of the acute wounds, 12.5% (n = 3) of the leg ulcers and 14.3% (n = 2) of the other chronic wounds completely healed before 4 weeks. Surface areas decreased on average by 76.4%, 63.5% and 44.2% at study endpoint respectively. For burns, 19 patients healed (95%) within 5-19 days. A total of 771 dressing changes were performed during the course of the study. Dressing application was considered as easy or very easy in 90% or more of the changes and there was no difficulty in removing the dressing in about 95% of the cases. Safety was good with five reports of a transitory local adverse event, probably dressing-related, being observed, two patients (2.2%) prematurely stopped treatment because of moderate periwound erythema. Urgotul is a highly promising new dressing which is currently undergoing further comparative clinical evaluation.

Other products you may be interested in



Methods of Payment:
via Paypal